← Back to Search

Small Molecule Inhibitor

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Revolution Medicines, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a drug called RMC-4630 on adults whose solid tumors have come back or didn't respond to previous treatments. The drug aims to slow or stop tumor growth by targeting a specific overactive pathway in cancer cells.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events (AEs)
Number of participants with dose limiting toxicities (DLTs)
Secondary study objectives
Accumulation Ratio
Area Under the Curve (AUC)
Cmax
+4 more

Side effects data

From 2022 Phase 1 & 2 trial • 113 Patients • NCT03989115
100%
diarrhoea
75%
decreased appetite
50%
dehydration
50%
dizziness
25%
thrombocytopenia
25%
oedema peripheral
25%
fatigue
25%
cough
25%
pleural effusion
25%
constipation
25%
vomiting
25%
dry mouth
25%
lymphocyte count decreased
25%
hypoalbuminaemia
25%
anaemia
25%
fall
25%
weight decreased
25%
hypophosphataemia
25%
dermatitis acneiform
25%
gait disturbance
25%
dyspnoea
25%
platelet count decreased
25%
hyponatraemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intermittent RMC-4630 140mg (D1D2) + Osimertinib 80mg (QD)
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 40mg QD (21/7)
Intermittent RMC-4630 140mg (D1D4) + Cobimetinib 20mg QD (21/7)
Intermittent RMC-4630 80mg (D1D4) + Cobimetinib 20mg QD (21/7)
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 20mg QD (21/7)
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 40mg (D1D2)
Intermittent RMC-4630 140mg (D1D2) + Cobimetinib 60mg D1D2
Intermittent RMC-4630 100mg (D1D2) + Osimertinib 80mg (QD)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RMC-4630Experimental Treatment1 Intervention
RMC-4630 for oral administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RMC-4630
2019
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

Revolution Medicines, Inc.Lead Sponsor
12 Previous Clinical Trials
3,221 Total Patients Enrolled
SanofiIndustry Sponsor
2,216 Previous Clinical Trials
4,047,499 Total Patients Enrolled
~19 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top